Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
BriaCell (Nasdaq:BCTX) is expanding its pipeline into ovarian cancer with Bria-OVA+™, a personalized, off-the-shelf, cell-based immunotherapy candidate. Bria-OVA+ is designed with extra immune-stimulating components and builds on the Bria-OTS+™ platform used in metastatic breast cancer.
Preclinical data from related candidate Bria-BRES+™ showed activation of adaptive and innate immunity, supporting platform potential. BriaCell has licensed ovarian cancer cell lines from ATCC and begun development activities for Bria-OVA+ for potential clinical use.
BriaCell (Nasdaq:BCTX) completed manufacturing clinical supplies of Bria-PROS+™, its next-generation, personalized, off-the-shelf cell-based immunotherapy candidate for prostate cancer. A $2 million non-dilutive NCI grant awarded in August 2025 supports manufacturing and planned clinical evaluation.
The company plans a Phase 1/2a prostate cancer trial in the coming months. Preclinical data show activation of adaptive and innate immunity. Bria-PROS+ leverages the Bria-OTS+ platform, which in breast cancer includes a reported durable complete resolution of a lung metastasis in one patient.
BriaCell (Nasdaq:BCTX) added Penn Medicine’s Abramson Cancer Center as a clinical site for its pivotal Phase 3 Bria-ABC study in advanced metastatic breast cancer.
The trial evaluates lead candidate Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, with overall survival as the primary endpoint and FDA Fast Track designation.
BriaCell (Nasdaq:BCTX) reported that its pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer has screened over 315 and enrolled over 230 patients. The trial’s primary endpoint is overall survival, with interim topline data expected in 2026 after 144 events. The Bria-IMT regimen holds FDA Fast Track status and has attracted growing interest from leading cancer centers, including independent highlight in a Nature Medicine article on trials expected to shape medicine in 2026.
BriaCell (Nasdaq: BCTX) added NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center as a clinical site in its pivotal Phase 3 Bria-ABC study for advanced metastatic breast cancer. The trial evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, with overall survival as the primary endpoint and an interim analysis planned after 144 patient events. Bria-IMT has received FDA Fast Track designation. ClinicalTrials.gov identifier: NCT06072612.
BriaCell (Nasdaq: BCTX) received FDA clearance of an Investigational New Drug application to begin a Phase 1/2a clinical study of Bria-BRES+ in metastatic breast cancer. The company has prepared clinical supplies and plans to start dosing in the coming months. Bria-BRES+ incorporates added immune-activating components and showed multiarm immune activation in preclinical data. BriaCell cites a prior Bria-OTS patient with a confirmed complete resolution of a lung metastasis after treatment.
BriaCell (Nasdaq: BCTX) announced six clinical data items at the 2026 ASCO Annual Meeting (May 29–June 2, 2026): three poster presentations and three publication-only abstracts covering survival, quality of life, biomarkers, and cell‑based immunotherapy in metastatic breast cancer.
Poster sessions occur May 30 and June 1, 2026; ASCO will publish abstracts May 21, 2026 at 5:00 PM ET. Poster copies will be posted at https://briacell.com/scientific-publications/ after presentation.
BriaCell (Nasdaq: BCTX) presented preclinical data for its Bria-OTS+ engineered whole-cell immunotherapy at AACR 2026 showing rapid activation of innate and adaptive immunity, durable cytokine responses, and sustained serial tumor-cell killing across breast and prostate models.
The company said Bria-OTS+ activated CD4+, CD8+, NK, NKT, dendritic and B cells, limited Treg and MDSC induction, demonstrated cross-tumor recognition, and plans to advance into clinical testing for metastatic breast and prostate cancer later in 2026.
BriaCell (Nasdaq: BCTX) presented Phase 3 quality-of-life and Phase 2 biomarker findings at AACR 2026 on April 20–21. The Phase 3 Bria-IMT + CPI data show QOL largely preserved in heavily pretreated metastatic breast cancer patients with prior ADC, CPI, and CDK4/6 exposure.
Phase 2 analyses identify mitotic circulating tumor cells as a potential prognostic biomarker and PD-L1 in tumor-macrophage fusion cells as a blood-based predictor of checkpoint inhibitor benefit. Posters and abstracts are available through the company.
BriaCell (Nasdaq: BCTX) reported an 11-month sustained complete resolution of a lung metastasis in the first patient enrolled in the Bria-OTS Phase 1/2a metastatic breast cancer study.
The 78-year-old hormone receptor-positive, HER2-negative patient achieved 100% resolution after four doses of Bria-OTS monotherapy, with the response first seen at 2 months and confirmed at 4, 6, and 11 months; the patient completed 12 months on study, received 17 cycles, reported no treatment-limiting toxicities, maintained stable disease at other evaluable sites, and remains in survival follow-up.
The Phase 1 dose-escalation is complete and the Phase 2a combination study with an immune checkpoint inhibitor is underway.